WINTON GROUP Ltd Sells 4,639 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

WINTON GROUP Ltd cut its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 21.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 16,674 shares of the biotechnology company’s stock after selling 4,639 shares during the period. WINTON GROUP Ltd’s holdings in BioMarin Pharmaceutical were worth $1,096,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in BMRN. Merit Financial Group LLC bought a new position in BioMarin Pharmaceutical in the 4th quarter valued at approximately $317,000. Assenagon Asset Management S.A. increased its position in BioMarin Pharmaceutical by 461.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company’s stock valued at $40,205,000 after acquiring an additional 502,695 shares during the period. Wedmont Private Capital bought a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at $430,000. Swedbank AB lifted its holdings in shares of BioMarin Pharmaceutical by 11.2% during the fourth quarter. Swedbank AB now owns 432,122 shares of the biotechnology company’s stock worth $28,403,000 after purchasing an additional 43,593 shares during the period. Finally, Tidal Investments LLC grew its stake in shares of BioMarin Pharmaceutical by 150.4% in the third quarter. Tidal Investments LLC now owns 30,467 shares of the biotechnology company’s stock worth $2,142,000 after purchasing an additional 18,300 shares during the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CAO Erin Burkhart sold 1,295 shares of the stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.52, for a total value of $92,618.40. Following the completion of the sale, the chief accounting officer now directly owns 16,955 shares of the company’s stock, valued at approximately $1,212,621.60. This represents a 7.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN stock opened at $71.44 on Friday. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The firm has a fifty day simple moving average of $67.46 and a two-hundred day simple moving average of $67.75. BioMarin Pharmaceutical Inc. has a 12 month low of $60.63 and a 12 month high of $94.85. The firm has a market capitalization of $13.63 billion, a PE ratio of 32.47, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. Analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Oppenheimer raised BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 target price on the stock in a report on Monday, February 24th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $70.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Bank of America raised their price target on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. StockNews.com raised shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 18th. Finally, UBS Group lifted their target price on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Seven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $94.00.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.